

CHANGES TO EBMT DATABASE BETWEEN June 2007 and February 2008

During the above period, For some diseases and for the Autograft and Allograft insert, there have been substantial changes following reviews of the clinical content made by the Definitions committee and the corresponding Working Party

For the rest of the diseases and other forms, there have only been small changes aimed at making the disease specific form compatible with the new Autograft and Allograft inserts, and at standardizing the Follow up set for the common items.

In addition the Med-A was substantially revised and the Med-A Appendix added

The table below summarises the changes:

Type of Form		Type of changes	Type of Form		Type of changes	Comments
Med-B	Allograft	Substantial	Med-B	Lymphoma	Substantial	
Med-B	Autograft	Substantial	Med-B	Multiple sclerosis	Minor	
Med-B	Acute leukaemia	Substantial	Med-B	MDS	Substantial	Separated from MPS
Med-B	Amyloidosis	Minor	Med-B	MPS	Substantial	Separated from MDS
Med-B	Aplastic anaemia	Minor	Med-B	Plasma cell disorders	Substantial	
Med-B	CML	Substantial	Med-B	Solid tumours	Minor	
Med-B	CLL	Substantial	Med-B	Systemic lupus erythematosus	Minor	
Med-B	Haemoglobinopathy	Minor	Med-B	Systemic sclerosis	Minor	
Med-B	Inherited disorders	Minor	Med-B	HLA	None	Included in new Allograft insert
Med-B	Juvenile idiopathic arthritis	Minor	Med-A	Med-A	Substantial	

Fields added for changes in Med-B and Med-A

Field name	Field description	TAG	Form affected	Other fields affected (if applicable)
AML	AML WHO classification	BB0C0D1	Acute leukaemia	
ALLL	ALL WHO classification	BB0C0F1	Acute leukaemia	
HODGKIN	Hodgkins type	BB0D0E1	Lymphoma	
ISS	ISS (<i>International Staging System</i>)	BB0G0G1	Plasma cell disorders	
REGTYPE	Type of registration	BB0I0A1	Aplastic anaemia	
HISTIOCY	Histiocytic disorders	BB0I2B1	Med-A	
REASTROT	Specify other reasons for the HSCT if there are more than one	BC0C0D1	CML	
DONNR	Number of donors / cords	BC0C0H1	Allograft	
MOABNST	T -cell depletion by monoclonal antibodies	BC0D1E1	Allograft	
MOABNSB	B -cell depletion by monoclonal antibodies	BC0D1F1	Allograft	
MOABNSNK	NK -cell depletion by monoclonal antibodies	BC0D1G1	Allograft	
GENEMANI	Gene manipulation	BC0D3C1	Allograft	
MYELOABR	Regimen intended to be myeloablative (<i>full intensity</i>)	BC0E1C1	Allograft	Obsolete: VREDINTE, Reduced intensity
REASRI	Reason for non myeloablative (<i>reduced intensity</i>) regimen	BC0E1E1	Allograft	
REASRIOT	Specify other reasons for non myeloablative if more than one	BC0E1H1	Allograft	
TLNADOSE	TLI / TNI / TAI total dose (Gy)	BC0E5D1	Allograft	
TLNADOSE	TLI / TNI / TAI total dose (Gy)	BC0E5D1	Autograft	
ADDPROT	Additional disease treatment	BC0F1A1	Acute leukaemia	
ADDPROT	Additional disease treatment	BC0F1A1	Amyloidosis	
ADDPROT	Additional disease treatment	BC0F1A1	Aplastic anaemia	
ADDPROT	Additional disease treatment	BC0F1A1	Autoimmune	
ADDPROT	Additional disease treatment	BC0F1A1	CLL	
ADDPROT	Additional disease treatment	BC0F1A1	CML	

Field name	Field description	TAG	Form affected	Other fields affected (if applicable)
ADDPROT	Additional disease treatment	BC0F1A1	Haemoglobinopathy	
ADDPROT	Additional disease treatment	BC0F1A1	Inherited disorders	
ADDPROT	Additional disease treatment	BC0F1A1	Lymphoma	
ADDPROT	Additional disease treatment	BC0F1A1	MDS, Secondary Ac Lk	
ADDPROT	Additional disease treatment	BC0F1A1	MPS	
ADDPROT	Additional disease treatment	BC0F1A1	Plasma cell disorders	
ADDPROT	Additional disease treatment	BC0F1A1	Solid tumours	
MESECHYM	Mesenchymal cells	BC0I1E1	Med-A	
MESECHYM	Mesenchymal cells	BC0I1E1	Allograft	
MESECHYM	Mesenchymal cells	BC0I1E1	Autograft	
ECP	Extracorporeal photopheresis (ECP)	BC0K0I1	Allograft	
MDSSTAG	MDS WHO classification	BE0B0A1	MDS, Secondary Ac Lk	
MDMPSTAG	MD/MP disorders WHO classification	BE0B0E1	MDS, Secondary Ac Lk	
WCLLBINE	Worst Binet stage up to and including this date	BE0B0O1	CLL	Obsolete: DATWDS, Worst status date prior to transplant
DATTRAN	Date of transformation	BE0B0Q1	MDS, Secondary Ac Lk	
DATTRAN	Date of transformation	BE0B0Q1	MPS	
MORE3AB	Are there more than 3 abnormalities (<i>complex karyotype</i>)?	BE0B3C1	Acute leukaemia	
MORE3AB	Are there more than 3 abnormalities (<i>complex karyotype</i>)?	BE0B3C1	MDS, Secondary Ac Lk	
MORE3AB	Are there more than 3 abnormalities (<i>complex karyotype</i>)?	BE0B3C1	MPS	
VHGENE	VH gene status	BE0B3G1	CLL	
VH321	VH3-21 status	BE0B3H1	CLL	
IPSS6	IPSS (<i>International prognostic scoring system</i>) for MDS	BE0C1D1	MDS, Secondary Ac Lk	
LILLES	Lille score	BE0C1E1	MPS	
CERVANS	Cervantes score	BE0C1F1	MPS	

Field name	Field description	TAG	Form affected	Other fields affected (if applicable)
SWEAT	Night sweat	BE0C4L1	MPS	
PURANARF	Purine analogue refractory	BE0E2F1	CLL	
EARREL	Early relapse after intensive therapy	BE0E2G1	CLL	
SMDASSAY	Sensitivity of minimal residual disease (MRD) assay	BE0K0R1	CLL	
DISCLI	Disease detected by clinical/haematological method	BE0K1E1	Acute leukaemia	
DISCLI	Disease detected by clinical/haematological method	BE0K1E1	Amyloidosis	
DISCLI	Disease detected by clinical/haematological method	BE0K1E1	Aplastic anaemia	
DISCLI	Disease detected by clinical/haematological method	BE0K1E1	Autoimmune	
DISCLI	Disease detected by clinical/haematological method	BE0K1E1	CLL	
DISCLI	Disease detected by clinical/haematological method	BE0K1E1	CML	
DISCLI	Disease detected by clinical/haematological method	BE0K1E1	Haemoglobinopathy	
DISCLI	Disease detected by clinical/haematological method	BE0K1E1	Inherited disorders	
DISCLI	Disease detected by clinical/haematological method	BE0K1E1	Lymphoma	
DISCLI	Disease detected by clinical/haematological method	BE0K1E1	MDS, Secondary Ac Lk	
DISCLI	Disease detected by clinical/haematological method	BE0K1E1	MPS	
DISCLI	Disease detected by clinical/haematological method	BE0K1E1	Plasma cell disorders	
DISCLI	Disease detected by clinical/haematological method	BE0K1E1	Solid tumours	

Field name	Field description	TAG	Form affected	Other fields affected (if applicable)
DISCLID	Date of last clinical/haematological assessment	BE0K1F1	Acute leukaemia	
DISCLID	Date of last clinical/haematological assessment	BE0K1F1	Amyloidosis	
DISCLID	Date of last clinical/haematological assessment	BE0K1F1	Aplastic anaemia	
DISCLID	Date of last clinical/haematological assessment	BE0K1F1	Autoimmune	
DISCLID	Date of last clinical/haematological assessment	BE0K1F1	CLL	
DISCLID	Date of last clinical/haematological assessment	BE0K1F1	CML	
DISCLID	Date of last clinical/haematological assessment	BE0K1F1	Haemoglobinopathy	
DISCLID	Date of last clinical/haematological assessment	BE0K1F1	Inherited disorders	
DISCLID	Date of last clinical/haematological assessment	BE0K1F1	Lymphoma	
DISCLID	Date of last clinical/haematological assessment	BE0K1F1	MDS, Secondary Ac Lk	
DISCLID	Date of last clinical/haematological assessment	BE0K1F1	MPS	
DISCLID	Date of last clinical/haematological assessment	BE0K1F1	Plasma cell disorders	
DISCLID	Date of last clinical/haematological assessment	BE0K1F1	Solid tumours	
DISCYTDR	Cytogenetic detection of disease considered relapse/progression	BE0K1I1	Acute leukaemia	
DISCYTDR	Cytogenetic detection of disease considered relapse/progression	BE0K1I1	CLL	
DISCYTDR	Cytogenetic detection of disease considered relapse/progression	BE0K1I1	CML	
DISCYTD	Date of last cytogenetic assessment	BE0K1J1	Acute leukaemia	
DISCYTD	Date of last cytogenetic assessment	BE0K1J1	CLL	
DISCYTD	Date of last cytogenetic assessment	BE0K1J1	CML	
NEGPOS	Negative or positive selection	CD0A0J1	Allograft	Field made obsolete: NEGPOSSE, Negative or positive selection
NEGPOS	Negative or positive selection	CD0A0J1	Autograft	Field made obsolete: NEGPOSSE, Negative or positive selection
ANIMORIG	Animal origin	CD0A1D1	Allograft	Complements field: ORIGIN, Other animal origin, specify
ANIMORIG	Animal origin	CD0A1D1	Autograft	Complements field: ORIGIN, Other animal origin, specify

Field name	Field description	TAG	Form affected	Other fields affected (if applicable)
ANIMORIG	Animal origin	CD0A1D1	Med-A	Complements field: ORIGIN, Other animal origin, specify
RADIOLB	Radiolabelled	CD0A1J1	Allograft	Field made obsolete: RADIOLAB, Radiolabelled
RADIOLB	Radiolabelled	CD0A1J1	Autograft	Field made obsolete: RADIOLAB, Radiolabelled
RADIOLB	Radiolabelled	CD0A1J1	Med-A	Field made obsolete: RADIOLAB, Radiolabelled
DOSERAD	Dose of radioactive antibody	CD0A1K1	Allograft	
DOSERAD	Dose of radioactive antibody	CD0A1K1	Autograft	
DOSERAD	Dose of radioactive antibody	CD0A1K1	Med-A	
DOSRADUN	Units of measurement of the radioactivity	CD0A1L1	Allograft	
DOSRADUN	Units of measurement of the radioactivity	CD0A1L1	Autograft	
DOSRADUN	Units of measurement of the radioactivity	CD0A1L1	Med-A	
DOSE	Dose of drug (new)	CD0A1O1	Allograft	Field made obsolete: DOSEDRUG, Dose of drug
DOSE	Dose of drug (new)	CD0A1O1	Autograft	Field made obsolete: DOSEDRUG, Dose of drug
DOSE	Dose of drug (new)	CD0A1O1	Med-A	Field made obsolete: DOSEDRUG, Dose of drug
DOSEUNIT	Units of measurement	CD0A1P1	Allograft	Field made obsolete: UNITS, Units of measurement
DOSEUNIT	Units of measurement	CD0A1P1	Autograft	Field made obsolete: UNITS, Units of measurement
DOSEUNIT	Units of measurement	CD0A1P1	Med-A	Field made obsolete: UNITS, Units of measurement
TCELLS	Number of T-cells	CF0A0F1	Acute leukaemia	
TCELLS	Number of T-cells	CF0A0F1	Amyloidosis	
TCELLS	Number of T-cells	CF0A0F1	Aplastic anaemia	
TCELLS	Number of T-cells	CF0A0F1	Autoimmune	
TCELLS	Number of T-cells	CF0A0F1	CLL	
TCELLS	Number of T-cells	CF0A0F1	CML	
TCELLS	Number of T-cells	CF0A0F1	Haemoglobinopathy	
TCELLS	Number of T-cells	CF0A0F1	Inherited disorders	
TCELLS	Number of T-cells	CF0A0F1	Lymphoma	
TCELLS	Number of T-cells	CF0A0F1	MDS, Secondary Ac Lk	
TCELLS	Number of T-cells	CF0A0F1	MPS	
TCELLS	Number of T-cells	CF0A0F1	Plasma cell disorders	

Field name	Field description	TAG	Form affected	Other fields affected (if applicable)
TCELLS	Number of T-cells	CF0A0F1	Solid tumours	
ALLMISSRL	Degree of allele mismatch in related donors	CH0A1D1	Allograft	
ALLMISSRL	Degree of allele mismatch in related donors	CH0A1D1	Med-A	
DONREGID	Name of the Donor registry or Cord blood bank	CH0A1F1	Allograft	
WMDAID	WMDA number	CH0A1G1	Allograft	
MMSERA	Number of antigenic mismatches: A	CH0A2B1	Allograft	
MMSERA	Number of antigenic mismatches: A	CH0A2B1	Med-A	
MMSERB	Number of antigenic mismatches: B	CH0A2C1	Allograft	
MMSERB	Number of antigenic mismatches: B	CH0A2C1	Med-A	
MMSERC	Number of antigenic mismatches: C	CH0A2D1	Allograft	
MMSERC	Number of antigenic mismatches: C	CH0A2D1	Med-A	
MMSERDR	Number of antigenic mismatches: DRB1	CH0A2E1	Allograft	
MMSERDR	Number of antigenic mismatches: DRB1	CH0A2E1	Med-A	
MMSERDQ	Number of antigenic mismatches: DQB1	CH0A2F1	Allograft	
MMSERDQ	Number of antigenic mismatches: DQB1	CH0A2F1	Med-A	
MMSERDP	Number of antigenic mismatches: DPB1	CH0A2G1	Allograft	
MMSERDP	Number of antigenic mismatches: DPB1	CH0A2G1	Med-A	
MMALLA	Number of allelic mismatches: A	CH0A2H1	Allograft	
MMALLA	Number of allelic mismatches: A	CH0A2H1	Med-A	
MMALLB	Number of allelic mismatches: B	CH0A2I1	Allograft	
MMALLB	Number of allelic mismatches: B	CH0A2I1	Med-A	
MMALLC	Number of allelic mismatches: C	CH0A2J1	Allograft	
MMALLC	Number of allelic mismatches: C	CH0A2J1	Med-A	
MMALLDR	Number of allelic mismatches: DRB1	CH0A2K1	Allograft	
MMALLDR	Number of allelic mismatches: DRB1	CH0A2K1	Med-A	
MMALLDQ	Number of allelic mismatches: DQB1	CH0A2L1	Allograft	
MMALLDQ	Number of allelic mismatches: DQB1	CH0A2L1	Med-A	
MMALLDP	Number of allelic mismatches: DPB1	CH0A2M1	Allograft	

Field name	Field description	TAG	Form affected	Other fields affected (if applicable)
MMALLDP	Number of allelic mismatches: DPB1	CH0A2M1	Med-A	
ABODON	Donor ABO blood group	CH0A2U1	Acute leukaemia	Field made obsolete: ABOMATCH, ABO Match
ABODON	Donor ABO blood group	CH0A2U1	Amyloidosis	Field made obsolete: ABOMATCH, ABO Match
ABODON	Donor ABO blood group	CH0A2U1	Aplastic anaemia	Field made obsolete: ABOMATCH, ABO Match
ABODON	Donor ABO blood group	CH0A2U1	Autoimmune	Field made obsolete: ABOMATCH, ABO Match
ABODON	Donor ABO blood group	CH0A2U1	CLL	Field made obsolete: ABOMATCH, ABO Match
ABODON	Donor ABO blood group	CH0A2U1	CML	Field made obsolete: ABOMATCH, ABO Match
ABODON	Donor ABO blood group	CH0A2U1	Haemoglobinopathy	Field made obsolete: ABOMATCH, ABO Match
ABODON	Donor ABO blood group	CH0A2U1	Inherited disorders	Field made obsolete: ABOMATCH, ABO Match
ABODON	Donor ABO blood group	CH0A2U1	Lymphoma	Field made obsolete: ABOMATCH, ABO Match
ABODON	Donor ABO blood group	CH0A2U1	MDS, Secondary Ac Lk	Field made obsolete: ABOMATCH, ABO Match
ABODON	Donor ABO blood group	CH0A2U1	MPS	Field made obsolete: ABOMATCH, ABO Match
ABODON	Donor ABO blood group	CH0A2U1	Plasma cell disorders	Field made obsolete: ABOMATCH, ABO Match
ABODON	Donor ABO blood group	CH0A2U1	Solid tumours	Field made obsolete: ABOMATCH, ABO Match
CHCODE1	Index code for new HLA type	CH0E0C1	Acute leukaemia	
CHCODE1	Index code for new HLA type	CH0E0C1	Amyloidosis	
CHCODE1	Index code for new HLA type	CH0E0C1	Aplastic anaemia	
CHCODE1	Index code for new HLA type	CH0E0C1	Autoimmune	
CHCODE1	Index code for new HLA type	CH0E0C1	CLL	
CHCODE1	Index code for new HLA type	CH0E0C1	CML	
CHCODE1	Index code for new HLA type	CH0E0C1	Haemoglobinopathy	
CHCODE1	Index code for new HLA type	CH0E0C1	Inherited disorders	
CHCODE1	Index code for new HLA type	CH0E0C1	Lymphoma	
CHCODE1	Index code for new HLA type	CH0E0C1	MDS, Secondary Ac Lk	
CHCODE1	Index code for new HLA type	CH0E0C1	MPS	
CHCODE1	Index code for new HLA type	CH0E0C1	Plasma cell disorders	
CHCODE1	Index code for new HLA type	CH0E0C1	Solid tumours	
COPIESM	Marker result (<i>copies/microg RNA</i>)	CL0A0D1	CML	

Field name	Field description	TAG	Form affected	Other fields affected <i>(if applicable)</i>
COPIESCG	Control gene result (<i>copies/microg RNA</i>)	CL0A0F1	CML	
MARCGR	Marker/control gene ratio	CL0A0H1	CML	
CUTOFF	Expression cut-off used (%)	CL0A0I1	CLL	

Where fields have been made obsolete, the information will be transferred to the new field.

Fields added for Med-A Appendix

Field name	Field description	TAG
ETHNIC1	Patient ethnicity	AA0B1B1
ETHNIC10	Patient race: White / caucasian	AA0B1C1
ETHNIC11	Patient race: Black / African American	AA0B1D1
ETHNIC12	Patient race: Oriental	AA0B1E1
ETHNIC13	American Indian / Alaska Native	AA0B1F1
ETHNIC14	Patient race: Native Hawaiian / Other Pacific Islander	AA0B1G1
MEDAPP	Med-A appendix to be entered	AA0C0A1
DISSECD1	Drugs or radiation related: Agents involved	BB0K1D1
COMORBID	Comorbid conditions	BE0C5A1
INBWDIS	Inflammatory bowel disease, previously present	BE0C5C1
RHEUMAT	Rheumatologic comorbidity	BE0C5D1
TRTDEPDB	Diabetes (<i>requiring treatment other than diet alone</i>)	BE0C5T1
KIDNEYCO	Renal comorbidity (<i>moderate to severe</i>)	BE0D0E1
HEPATIC	Hepatic comorbidity	BE0D1P1
VALVE	Heart valve disease	BE0D2M1
PULMONC	Pulmonary comorbidity	BE0D2T1
OBESITY	Obesity	BE0D4G1
PEPTICU	Peptic ulcer	BE0D4H1
PSYCH	Psychiatric disturbance	BE0D6R1

Fields no longer in use

These fields are no longer part of the Registry. They have been kept and the data has not been removed. Where data has been copied to other fields, that field appears under **Copied into**

Field name	Field description	TAG	Copied into
PERMISS	Patient asked to consent to data submission?	AA0A1H1	
VIBMTR	Registration to be sent to CIBMTR?	AA0A1J1	
STUDTRAN	Indicate which transplant is included in this study	BA0A0E1	
NBTRIAL	Number of patient in trial	BA0A0G1	
STUDSPEC	Specify details	BA0A0H1	
VAML	AML: FAB classification	BB0C0B1	
VAMLM5	AML: FAB M5 Type	BB0C0C1	
VCMLSUB	CML subclassification	BB0C1B1	
VDIFMEDB	Mediastinal large B cell?	BB0D0B1	VREALCLS
VINTRLBC	Intravascular large B cell?	BB0D0C1	VREALCLS
DATENDT	Date end therapy	BC0B3B1	
CRYOPRES	Cryopreservation of cells	BC0C2K1	
VCHEMPRO	Chemoprotection	BC0D1N1	
REDINTEC	Reduced intensity chemotherapy	BC0E2B1	MYELOABR
VREDINTB	Reduced intensity TBI	BC0E2G1	
SEROCON	Serotherapy	BC0E5K1	
VAGVHDP1	T-cell depletion in vivo	BC0K0B1	VAGVHDP5
VAGVHDP2	T-cell depletion with MoAb	BC0K0C1	VAGVHDP5
VAGVHDP3	Other T-cell depletion in vivo	BC0K0D1	VAGVHDP5
VAGVHDP4	Other T-cell depletion: specify	BC0K0E1	
VTRAGVH1	Chemo treatment for aGvHD	BC0K2C1	VTRAGVH2
DOUBTIME	Lymphocyte doubling time	BE0B4Y1	
VDAGT	DAGT (Direct antiglobulin test)	BE0B5A1	
ENGLAUC	Leucocytes > 1 x 10 ⁹ /L reached?	BE0H1C1	

Field name	Field description	TAG	Copied into
DLEUCDW	Date leucocytes < 1	BE0H1D1	
DLEUCEN	Date leucocytes > 1	BE0H1E1	
MOABDONE	Antibody given	CE0A0B1	DRUGDONE
RADIOLAB	Radiolabelled	CE0A0D1	RADIOLB
INEXVIVO	Monoclonal antibody in-vivo or ex-vivo	CE0A0E1	INEXVIVT
NEGPOSSE	Negative or positive selection	CE0A0F1	NEGPOS
VMOABPSS	Other antibody: specify	CE0A0G1	OTHECHEM
MOABREAS	Reason for this the antibody	CE0A0H1	REASDRUG
DOSEMOAB	Dose of MoAB	CE0A0I1	DOSE
UNITSM	Units of measurement	CE0A0J1	DOSEUNIT
MOABSTAR	Start date of antibody treatment	CE0A0K1	TRETSTAR
MOABEND	End date of antibody treatment	CE0A0L1	VINTBTDE
ABOMATCH	ABO Match	CH0A2V1	

Notes

Data transfer permissions

The fields used to trace permission of data transfer from patient to EBMT and from centre to CIBMTR have been removed. These permissions must be in place for data to be transferred. It is the responsibility of the transplant centre to ensure the patient has consented before the data is sent to the EBMT. The EBMT will not transfer data to the CIBMTR unless permission in writing has been granted by the centre.

Monoclonal antibody table.

This table is no longer in use. All its information has been copied to the chemotherapy table. Overall, an attempt is being made to put all therapies involving drugs, agents, chemo, MoAB, polyclonal AB, etc. under one general heading, while allowing for each specific one to be described in the chemotherapy table.

Absolute neutrophil recovery and Engraftment

The term "Engraftment" is being replaced by the term "Absolute neutrophil recovery (ANC)", which is more precise, since engraftment may refer to other types of cells, and also, since engraftment would need chimaerism to be done in order for it to be properly assessed in allografts.

Cell therapy

It is understood that there are cases of autologous cell therapy (other than HSCT), so this part has been added to the Med-B Auto form.